CA-XRAN-FOUNDATION
27.2.2017 08:03:01 CET | Business Wire | Press release
The xRAN Foundation, a consortium dedicated to promoting a software-based, extensible Radio Access Network (xRAN) and to standardizing critical elements of the xRAN architecture, today announced that Verizon, a global leader of innovative mobile communications, technology and infrastructure and Ranzure, a provider of flexible, virtualized, cloud-based 4G/5G RAN solutions, have joined the xRAN Foundation. In addition to these key new members, the xRAN Foundation has announced a collaboration with M-CORD , the open source project reinventing network access to bring datacenter economics and cloud agility to service providers’ central offices.
“A network architecture that provides a robust, interactive abstraction layer between applications and RAN infrastructure fits very well with our vision and goals. We believe this approach creates opportunities to increase the efficiency of our network and improve the quality of experience for our subscribers,” said Adam Koeppe, Vice President, Network Technology Planning at Verizon. “The xRAN Foundation has demonstrated the feasibility of a decoupled approach. The combination of standardized north-bound and south-bound interfaces allows the development of applications that can intelligently interact with the RAN infrastructure in a way that has never been possible before. We are excited to join the xRAN Foundation and plan to actively evaluate solutions that support xRAN interfaces and architecture.”
“For an efficient delivery of next generation mobile services, such as AR, IoT and industrial robotics, a new more flexible software-based and hardware independent RAN architecture is required. The xRAN approach will offer us real time programmability and control of our RAN infrastructure to dynamically adapt to our customers' needs,” said Bruno Jacobfeuerborn, CTO, Deutsche Telekom. “We are excited to see xRAN and CORD Project join forces to drive the development of this approach.”
Formally formed in October of 2016 by AT&T, Deutsche Telekom, SK Telecom, Intel Corporation, Texas Instruments, Radisys, Aricent and Stanford University, the xRAN Foundation is a consortium dedicated to promoting a software-based, extensible Radio Access Network (xRAN) and to standardizing critical elements of the xRAN architecture. The xRAN architecture transforms today’s static, highly-proprietary RAN infrastructure into an extensible, software-based service delivery platform capable of rapidly responding to changing user, application and business needs.
The xRAN Foundation is holding a panel discussion event at Mobile World Congress 2017 in Barcelona on Tuesday February 28th at noon on the Deutsche Telekom main presentation stage in Hall 3. The event will include an introduction presentation by Deutche Telekom CTO, Bruno Jacobfeuerborn, followed by a panel discussion moderated by Petr Ledl, Head of Deutsche Telekom 5G:haus. The panel includes Dr. Sachi Katti, Stanford University, Dr. Kim Larsen, Technology Economics & Transformation (TET) & AI Technology Architecture & Innovation (TAI) Group Technology at Deutsche Telekom, Gordon Mansfield, Vice President RAN & Device Design at AT&T, and Caroline Chan, VP and GM, 5G Infrastructure Division, Network Platform Group, at Intel.
A multi-vendor demonstration of the xRAN controller, featuring the Intel + Radisys and the Texas Instruments + Aricent reference platforms, will be hosted during Mobile World Congress. Register for a demo here: http://xran.org/mwc
About xRAN Foundation
The xRAN Foundation was formed to develop, standardize and promote an open alternative to the traditionally closed, hardware-based RAN architecture. xRAN fundamentally advances RAN architecture in three areas – decouples the RAN control plane from the user plane, builds a modular eNB software stack that operates on common-off-the-shelf (COTS) hardware and publishes open north- and south-bound interfaces to the industry. For more information about xRAN Foundation membership go to xran.org/membership or email info@xran.org . For more information on xRAN architecture, download the xRAN Architecture white paper . To schedule a briefing with xRAN member representatives at Mobile World Congress in Barcelona, please contact pr@xran.org .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170226005155/en/
Contact:
xRAN Foundation
Rod Stuhlmuller
rod@xran.org
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom